K-STREET TRACKER
FOLLOW THE MONEY INTO THE SWAMP
Every federal lobbying filing tagged with a public-company ticker — who is spending, which firms they hire, and which members trade right around the filing.
Filings tracked
19,882
thru 2026-05-08
Total reported $
$2.7B
disclosed lobbying
Distinct clients
2,220
paying companies
Tickers targeted
1,207
public companies
💸 Top Spending Clients
| # | Client | Filings | Total $ |
|---|---|---|---|
| 1 |  PFIZER INC.PFE | 47 | $46.8M |
| 2 |  GENERAL MOTORS COMPANYGM | 61 | $46.8M |
| 3 |  META PLATFORMS INC. AND VARIOUS SUBSIDIARIESMETA | 12 | $44.9M |
| 4 | VISA INC.V | 45 | $37.7M |
| 5 |  AMAZON.COM SERVICES LLCAMZN | 36 | $32.8M |
| 6 |  LOCKHEED MARTIN CORPORATIONLMT | 73 | $29.0M |
| 7 |  FEDEX CORPORATIONFDX | 69 | $27.8M |
| 8 |  ELI LILLY AND COMPANYLLY | 56 | $27.1M |
| 9 |  ALTRIA CLIENT SERVICES LLCMO | 142 | $25.2M |
| 10 |  AMGEN INCAMGN | 19 | $24.9M |
| 11 |  COMCAST CORPORATIONCMCSV | 179 | $24.7M |
| 12 |  MERCK & CO INCMRK | 14 | $24.0M |
| 13 |  SOUTHERN COMPANYSO | 53 | $23.9M |
| 14 |  GOOGLE CLIENT SERVICES LLCGOOGL | 79 | $22.6M |
| 15 |  APPLE INCAAPL | 9 | $22.1M |
| 16 |  T-MOBILE USA INC.TMUS | 121 | $21.0M |
| 17 |  UNITEDHEALTH GROUP INCUNH | 19 | $20.4M |
| 18 |  VERIZON COMMUNICATIONS INC AND VARIOUS SUBSIDIARIESVZ | 40 | $20.1M |
| 19 |  OCCIDENTAL PETROLEUM CORPORATIONOXY | 30 | $19.7M |
| 20 |  MICROSOFT CORPORATIONMSFT | 103 | $18.8M |
| 21 |  QUALCOMM INCORPORATEDQCOM | 40 | $17.2M |
| 22 |  GENERAL DYNAMICS CORPGD | 11 | $17.0M |
| 23 |  BOEING COMPANYBA | 23 | $16.9M |
| 24 | THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)CI | 13 | $16.9M |
| 25 |  ORACLE CORPORATIONORCL | 58 | $16.7M |
🎯 Top Lobbied Tickers
| # | Ticker | Filings | Total $ |
|---|---|---|---|
| 1 | META Meta Platforms Inc. | 129 | $50.2M |
| 2 | PFE Pfizer Inc. | 87 | $48.6M |
| 3 | GM General Motors Company | 103 | $48.4M |
| 4 | V Visa Inc. | 46 | $37.7M |
| 5 | AMZN Amazon.com Inc. | 80 | $35.3M |
| 6 | LMT Lockheed Martin Corporation | 88 | $29.4M |
| 7 | FDX FedEx Corporation | 82 | $28.3M |
| 8 | LLY Eli Lilly and Company | 83 | $28.1M |
| 9 | AMGN Amgen Inc. | 95 | $28.0M |
| 10 | MRK Merck & Co. Inc. | 92 | $27.5M |
| 11 | AAPL Apple Inc. | 64 | $26.8M |
| 12 | GOOGL Alphabet Inc. Class A | 123 | $26.6M |
| 13 | MO | 164 | $26.2M |
| 14 | SO Southern Company | 108 | $26.1M |
| 15 | UNH UnitedHealth Group Inc. | 67 | $23.9M |
| 16 | VZ Verizon Communications Inc. | 116 | $23.8M |
| 17 | TMUS | 159 | $22.7M |
| 18 |  CHTR | 137 | $22.6M |
| 19 | GD General Dynamics Corporation | 127 | $22.5M |
| 20 |  TAT&T Inc. | 134 | $21.6M |
| 21 | ORCL Oracle Corporation | 132 | $20.6M |
| 22 | CMCSA Comcast Corporation | 141 | $20.4M |
| 23 | CI The Cigna Group | 64 | $19.9M |
| 24 | OXY Occidental Petroleum Corporation | 36 | $19.9M |
| 25 | MSFT Microsoft Corporation | 122 | $19.2M |
🆕 Filtered Filings · ABBVIE INC.
clear filters| Date | Ticker | Client | Registrant | Amount | Issue |
|---|---|---|---|---|---|
| 2026-04-20 | ABBV | ABBVIE INC. | ABBVIE, INC. | $2.1M | S.1040, Drug Competition Enhancement Act Patent litigation reform issues and issues related to post-grant proceedings at the USPTO Value of intellectual property S. 864, HELP Copays Act H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act S. 2903, Safe Step Act H.R. 5509, Safe Step Act Drug cost and pricing policy issues Patient affordability issues Issues related to the 340B program Issues related to data privacy Issues related to Hepatitis C elimination Issues related to FDA communications Public Law 117-169 (formerly known as H.R. 5376, Inflation Reduction Act) Implementation regarding Medicare Part D drug negotiation program Policy Proposals related to Medicare Part D and patient cost-sharing Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues Issues related to HCV treatment H.R. 1328, Supply Chain Security and Growth Act of 2025 H.R. 1990, American Innovation and R&D Competitiveness Act of 2025 Public Law No: 119- |
| 2026-04-20 | ABBV | ABBVIE INC. | TARPLIN, DOWNS & YOUNG, LLC | $60K | drug pricing in federal programs, transparency, prescription drug pricing and access, beneficiary access, IRA Part B, Part D, drug pricing and access, negotiation, federal budget issues |
| 2026-04-20 | ABBV | ABBVIE INC. | W STRATEGIES, LLC | $50K | Education and legislation related to reform of the 340(b) program. Education around data privacy. Medicare Implementation of the Inflation Reduction Act. Public Law 119-21: One Big Beautiful Bill Act. Issues around drug pricing. |
| 2026-04-20 | ABBV | ABBVIE INC. | FEDERAL STREET STRATEGIES, LLC | $50K | Patient Access to drug treatment therapies; and drug cost and drug pricing reform. Oversight of the pharmaceutical industry and drug pricing. Policies as they relate to PBMs Issues related to the budget and appropriations process Medicare Part D policies. Monitoring Policies related to the 340b program. Issues related to the implementation of the Inflation Reduction Act Issues related to the budget and appropriations process |
| 2026-04-20 | ABBV | ABBVIE INC. | WILLIAMS AND JENSEN, PLLC | $30K | 340B Reform, FDA drug approvals, monitoring Food is Medicine initiatives, importation of biopharmaceutical products, pharmaceutical supply chain. Prescription drug advertising issues. Drug pricing policies, implementation of IRA drug pricing policies, access and coverage, most-favored nation drug pricing policies, ORPHAN Cures Act implementation. Monitoring 232 investigations, monitoring tariffs, most favored nation drug pricing policies, pharmaceutical IP issues. H.R.830/S. 864, HELP Copays Act of 2023; Pharmacy Benefit Manager transparency, including Lower Costs, More Transparency Act, monitoring efforts around direct-to-consumer policies. |
| 2026-04-19 | ABBV | ABBVIE INC. | CHECKMATE GOVERNMENT RELATIONS | $180K | Issues regarding life sciences related matters. Issues regarding life sciences related matters. |
| 2026-04-19 | ABBV | ABBVIE INC. | BAKER & HOSTETLER LLP | $0 | |
| 2026-04-17 | ABBV | ABBVIE INC. | MARSHALL & POPP, LLC | $60K | Issues related to the 340B drug discount program. Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to FDA regulation of pharmaceuticals. |
| 2026-04-08 | ABBV | ABBVIE INC. | CORNERSTONE GOVERNMENT AFFAIRS, INC. | $80K | International tax issues and pharmaceutical pricing and access issues, and patent issues. International tax issues and pharmaceutical pricing and access issues, and patent issues. |
| 2026-03-20 | ABBV | ABBVIE INC. | WILLIAMS AND JENSEN, PLLC | $0 | Providing strategic counsel on congressional and administrative issues, including drug pricing, Medicare and Medicaid, 340B, tax and trade, intellectual property, and FDA regulatory matters. |
| 2026-02-11 | ABBV | ABBVIE INC. | CHECKMATE GOVERNMENT RELATIONS | $0 | Issues regarding life sciences related matters. Issues regarding life sciences related matters. |
| 2026-01-20 | ABBV | ABBVIE INC. | ABBVIE, INC. | $1.3M | S.1040, Drug Competition Enhancement Act Patent litigation reform issues and issues related to post-grant proceedings at the USPTO Value of intellectual property S. 864, HELP Copays Act H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act Drug cost and pricing policy issues Patient affordability issues Issues related to the 340B program Issues related to data privacy Issues related to Hepatitis C elimination Public Law 117-169 (formerly known as H.R. 5376, Inflation Reduction Act) Implementation regarding Medicare Part D drug negotiation program Policy Proposals related to Medicare Part D and patient cost-sharing Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues Issues related to HCV treatment Issues related to Parkinsons pharmaceutical innovation H.R. 1328, Supply Chain Security and Growth Act of 2025 H.R. 1990, American Innovation and R&D Competitiveness Act of 2025 Public Law No: 119-21 (formerly known as H.R. 1, |
| 2026-01-20 | ABBV | ABBVIE INC. | TARPLIN, DOWNS & YOUNG, LLC | $60K | drug pricing in federal programs, transparency, prescription drug pricing and access, beneficiary access, IRA Part B, Part D, drug pricing and access, negotiation, federal budget issues |
| 2026-01-20 | ABBV | ABBVIE INC. | W STRATEGIES, LLC | $50K | Education and legislation related to reform of the 340(b) program. Education around data privacy. Medicare Implementation of the Inflation Reduction Act. Public Law 119-21: One Big Beautiful Bill Act. Issues around drug pricing. |
| 2026-01-20 | ABBV | ABBVIE INC. | FEDERAL STREET STRATEGIES, LLC | $50K | Patient Access to drug treatment therapies; and drug cost and drug pricing reform. Oversight of the pharmaceutical industry and drug pricing. Policies as they relate to PBMs Issues related to the FY2026 budget and appropriations process Medicare Part D policies. Monitoring Policies related to the 340b program. Issues related to the implementation of the Inflation Reduction Act Issues related to the FY2026 budget and appropriations process |
| 2026-01-19 | ABBV | ABBVIE INC. | BAKER & HOSTETLER LLP | $60K | Multiple tax policies, including provisions of Public Law No. 115-97 and Public Law No. 119-21. Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. |
| 2026-01-16 | ABBV | ABBVIE INC. | MARSHALL & POPP, LLC | $60K | Issues related to the 340B drug discount program. Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to FDA regulation of pharmaceuticals. |
| 2026-01-05 | ABBV | ABBVIE INC. | CORNERSTONE GOVERNMENT AFFAIRS, INC. | $60K | International tax issues and pharmaceutical pricing and access issues, and patent issues. International tax issues and pharmaceutical pricing and access issues, and patent issues. |
| 2025-10-20 | ABBV | ABBVIE INC. | ABBVIE, INC. | $980K | Issues related to pharmaceutical tariffs and unfair trade practices S.1040, Drug Competition Enhancement Act Patent litigation reform issues and issues related to post-grant proceedings at the USPTO Value of intellectual property S. 864, HELP Copays Act Drug cost and pricing policy issues Patient affordability issues Issues related to the 340B program Issues related to data privacy Public Law 117-169 (formerly known as H.R. 5376, Inflation Reduction Act) Implementation regarding Medicare Part D drug negotiation program Policy Proposals related to Medicare Part D and patient cost-sharing Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues Issues related to HCV treatment H.R. 1328, Supply Chain Security and Growth Act of 2025 H.R. 1990, American Innovation and R&D Competitiveness Act of 2025 Public Law No: 119-21 (formerly known as H.R. 1, One Big Beautiful Bill Act) Implementation Public Law 115-97 (formerly known as H.R. 1, Tax Cuts and |
| 2025-10-20 | ABBV | ABBVIE INC. | MARSHALL & POPP, LLC | $60K | Issues related to the 340B drug discount program. Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169) and H.R.1, FY25 budget reconciliation. |
| 2025-10-20 | ABBV | ABBVIE INC. | BAKER & HOSTETLER LLP | $60K | Multiple tax policies, including provisions of Public Law No. 115-97 and Public Law No. 119-21. Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. |
| 2025-10-20 | ABBV | ABBVIE INC. | W STRATEGIES, LLC | $50K | Education and legislation related to reform of the 340(b) program. Education around data privacy. Medicare Implementation of the Inflation Reduction Act. Public Law 119-21: One Big Beautiful Bill Act. |
| 2025-10-20 | ABBV | ABBVIE INC. | FEDERAL STREET STRATEGIES, LLC | $50K | Patient Access to drug treatment therapies; and drug cost and drug pricing reform. Oversight of the pharmaceutical industry and drug pricing. Monitoring policies as they relate to PBMs Monitor issues related to the FY2026 budget process Medicare Part D policies. Monitoring Policies related to the 340b program. Issues related to the implementation of the Inflation Reduction Act Monitor issues related to the FY2026 budget process |
| 2025-10-16 | ABBV | ABBVIE INC. | TARPLIN, DOWNS & YOUNG, LLC | $60K | drug pricing in federal programs, transparency, prescription drug pricing and access, beneficiary access, IRA Part B, Part D, drug pricing and access, negotiation, federal budget issues |
| 2025-10-09 | ABBV | ABBVIE INC. | CORNERSTONE GOVERNMENT AFFAIRS, INC. | $60K | International tax issues and pharmaceutical pricing and access issues, and patent issues. International tax issues and pharmaceutical pricing and access issues, and patent issues. |
| 2025-07-21 | ABBV | ABBVIE INC. | ABBVIE, INC. | $1.2M | S.1040, Drug Competition Enhancement Act Patent litigation reform issues and issues related to post-grant proceedings at the USPTO Value of intellectual property S. 864, HELP Copays Act Drug cost and pricing policy issues Patient affordability issues Issues related to the 340B program Public Law 117-169 (formerly known as H.R. 5376, Inflation Reduction Act) Implementation regarding Medicare Part D drug negotiation program Policy Proposals related to Medicare Part D and patient cost-sharing Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues Issues related to HCV treatment H.R. 1328, Supply Chain Security and Growth Act of 2025 H.R. 1990, American Innovation and R&D Competitiveness Act of 2025 H.R. 1, One Big Beautiful Bill Act Public Law 115-97 (formerly known as H.R. 1, Tax Cuts and Jobs Act) Implementation Policy proposals relating to economic activity in Puerto Rico International tax issues, including OECD digital taxation work program |
| 2025-07-21 | ABBV | ABBVIE INC. | MARSHALL & POPP, LLC | $60K | Issues related to the 340B drug discount program. Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169) and H.R.1, FY25 budget reconciliation. |
| 2025-07-21 | ABBV | ABBVIE INC. | TARPLIN, DOWNS & YOUNG, LLC | $60K | 340B, transparency, prescription drug pricing and access, beneficiary access, IRA Part B, Part D, drug pricing and access, negotiation federal budget issues |
| 2025-07-21 | ABBV | ABBVIE INC. | BAKER & HOSTETLER LLP | $60K | Multiple tax policies, including provisions of the Tax Cuts and Jobs Act. Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. |
| 2025-07-21 | ABBV | ABBVIE INC. | FEDERAL STREET STRATEGIES, LLC | $50K | Patient Access to drug treatment therapies; and drug cost and drug pricing reform. Oversight of the pharmaceutical industry and drug pricing. Monitoring policies as they relate to PBMs Monitor issues related to the FY2025 budget reconciliation process Medicare Part D policies. Monitoring Policies related to the 340b program. Issues related to the implementation of the Inflation Reduction Act Monitor issues related to the FY2025 budget reconciliation process |
| 2025-07-18 | ABBV | ABBVIE INC. | W STRATEGIES, LLC | $50K | Education and legislation related to reform of the 340(b) program. Medicare Implementation of the Inflation Reduction Act. H.R.1 - One Big Beautiful Bill Act. |
| 2025-07-10 | ABBV | ABBVIE INC. | CORNERSTONE GOVERNMENT AFFAIRS, INC. | $60K | International tax issues and pharmaceutical pricing and access issues, and patent issues. International tax issues and pharmaceutical pricing and access issues, and patent issues. |
| 2025-04-21 | ABBV | ABBVIE INC. | ABBVIE, INC. | $2.1M | S. 1096, Preserve Access to Affordable Generics and Biosimilars Act Patent litigation reform issues and issues related to post-grant proceedings at the USPTO Value of intellectual property S. 864, HELP Copays Act Drug cost and pricing policy issues Patient affordability issues Issues related to the 340B program Public Law 117-169 (formerly known as H.R. 5376, Inflation Reduction Act) Implementation regarding Medicare Part D drug negotiation program and smoothing out-of-pocket costs for patients Policy Proposals related to Medicare Part D and patient cost-sharing Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues Issues related to HCV treatment H.R. 1328, Supply Chain Security and Growth Act of 2025 H.R. 1990, American Innovation and R&D Competitiveness Act of 2025 Public Law 115-97 (formerly known as H.R. 1, Tax Cuts and Jobs Act) Implementation Policy proposals relating to economic activity in Puerto Rico International tax issues, inclu |
| 2025-04-21 | ABBV | ABBVIE INC. | BAKER & HOSTETLER LLP | $60K | Multiple tax policies, including provisions of the Tax Cuts and Jobs Act. Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. |
| 2025-04-21 | ABBV | ABBVIE INC. | FEDERAL STREET STRATEGIES, LLC | $50K | Patient Access to drug treatment therapies; and drug cost and drug pricing reform. Oversight of the pharmaceutical industry and drug pricing. Monitoring policies as they relate to PBMs Medicare Part D policies. Monitoring Policies related to the 340b program. Issues related to the implementation of the Inflation Reduction Act |
| 2025-04-21 | ABBV | ABBVIE INC. | MARSHALL & POPP, LLC | $0 | |
| 2025-04-20 | ABBV | ABBVIE INC. | TARPLIN, DOWNS & YOUNG, LLC | $60K | 340B, transparency, prescription drug pricing and access, beneficiary access, IRA Part B, Part D, drug pricing and access, negotiation federal budget issues |
| 2025-04-18 | ABBV | ABBVIE INC. | W STRATEGIES, LLC | $50K | Education and legislation related to reform of the 340(b) program. Medicare Implementation of the Inflation Reduction Act. |
| 2025-04-04 | ABBV | ABBVIE INC. | CORNERSTONE GOVERNMENT AFFAIRS, INC. | $60K | International tax issues and pharmaceutical pricing and access issues, and patent issues. International tax issues and pharmaceutical pricing and access issues, and patent issues. |
| 2025-01-21 | ABBV | ABBVIE INC. | ABBVIE, INC. | $1.1M | S. 142, Preserve Access to Affordable Generics and Biosimilars Act S. 2780, Medication Affordability and Patent Integrity Act Patent litigation reform issues and issues related to post-grant proceedings at the USPTO Value of intellectual property H.R. 830, HELP Copays Act S.1375, HELP Copays Act H.R. 5378, Lower Costs, More Transparency Act S. 1339, Pharmacy Benefit Manager Reform Act Drug cost and pricing policy issues Patient affordability issues Policy proposals relating to clinical trial diversity Issues related to the 340B program H.R. 8816, American Medical Innovation and Investment Act of 2024 Public Law 117-169 (formerly known as H.R. 5376, Inflation Reduction Act) Implementation regarding Medicare Part D drug negotiation program and smoothing out-of-pocket costs for patients Policy Proposals related to Medicare Part D and patient cost-sharing Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues H.R. 2673, American Innovation and R |
| 2025-01-21 | ABBV | ABBVIE INC. | MARSHALL & POPP, LLC | $60K | Issues related to the 340B drug discount program. Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169). Issues related to the 340B drug discount program. Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169). |
| 2025-01-21 | ABBV | ABBVIE INC. | TARPLIN, DOWNS & YOUNG, LLC | $60K | 340B, transparency, prescription drug pricing and access, beneficiary access, IRA implementation Part B, Part D, drug pricing and access, negotiation Federal budget issues |
| 2025-01-21 | ABBV | ABBVIE INC. | W STRATEGIES, LLC | $50K | Education and legislation related to reform of the 340(b) program. H.R.830 - HELP Copays Act. Medicare Implementation of the Inflation Reduction Act. |
| 2025-01-21 | ABBV | ABBVIE INC. | FEDERAL STREET STRATEGIES, LLC | $50K | Patient Access to drug treatment therapies; and drug cost and drug pricing reform. Oversight of the pharmaceutical industry and drug pricing. H.R.830 - HELP Copays Act S. 1375 - HELP Copays Act Monitoring policies as they relate to PBMs Transparency of prescription drug pricing; and patient costs of prescription drugs. Medicare Part D policies. Monitoring Policies related to the 340b program. Issues related to the implementation of the Inflation Reduction Act |
| 2025-01-20 | ABBV | ABBVIE INC. | BAKER & HOSTETLER LLP | $60K | Multiple tax policies, including provisions of the Tax Cuts and Jobs Act. Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. |